[1] Liubomirski Y, Ben-Baruch A. Notch-inflammation networks in regulation of breast cancer progression.Cells,2020,9(7):1576. [2] Liubomirski Y, Lerrer S, Meshel T, et al. Notch-mediated tumor-stroma-inflammation networks promote invasive properties and CXCL8 expression in triple-negative breast Cancer.Front Immunol,2019,10:804. [3] Chen W, Liu Y, Chen J, et al. The Notch signaling pathway regulates macrophage polarization in liver diseases. Int Immunopharmacol,2021,99:107938. [4] Zhou B, Lin W, Long Y, et al. Notch signaling pathway: architecture, disease, and therapeutics.Signal Transduct Target Ther,2022,7(1):95. [5] Richter L R, Wan Q, Wen D, et al. Targeted delivery of Notch inhibitor attenuates obesity-induced glucose intolerance and liver fibrosis. ACS Nano,2020,14(6):6878-6886. [6] Ding WJ, Wu WJ, Chen YW, et al. Expression of Notch family is altered in nonalcoholic fatty liver disease. Mol Med Rep,2020;22(3):1702-1708. [7] 吴伟杰,陈源文,丁雯瑾,等.体外脂肪变L02细胞Notch家族和脂质代谢变化研究.实用肝脏病杂志,2021,24(5):653-656. [8] Adams J M, Jafar-Nejad H. The roles of Notch signaling in liver development and disease.Biomolecules,2019,9(10): 608. [9] Xu H, Wang L. The role of Notch signaling pathway in non-alcoholic fatty liver disease. Front Mol Biosci,2021,8:792667. [10] Zhu C, Kim K, Wang X, et al. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis.Sci Transl Med,2018,10(468):eaat0344. [11] Lee YA, Friedman SL. Inflammatory and fibrotic mechanisms in NAFLD-implications for new treatment strategies. J Intern Med,2022,291(1):11-31. [12] Luna-Castillo KP, Olivares-Ochoa XC, Hernández-Ruiz RG, et al. The effect of dietary interventions on hypertriglyceridemia: from public health to molecular nutrition evidence.Nutrients,2022,14(5):1104. [13] Pajvani UB, Shawber CJ, Samuel VT, et al. Inhibition of Notch signaling ameliorates insulin resistance in a Foxo1-dependent manner.Nat Med,2011,17(8):961-967. [14] Kitamoto T, Lee YK, Sultana N, et al., Chemical induction of gut β-like-cells by combined FoxO1/Notch inhibition as a glucose-lowering treatment for diabetes.Mol Metab,2022,66:101624. [15] Zhang M, Wu P, Li M, et al. Inhibition of Notch1 signaling reduces hepatocyte injury in non-alcoholic fatty liver disease via autophagy.Biochem Biophys Res Commun,2021,547:131-138. [16] Bi P, Kuang S. Notch signaling as a novel regulator of metabolism.Trends Endocrinol Metab,2015,26(5):248-255. [17] Jz AL, Alshammari GM, Alfaris NA, et al. Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK.Pharm Biol,2022,60(1):25-37. [18] Aguayo-Ortiz R, Guzmán-Ocampo DC, Dominguez L. Toward the characterization of DAPT interactions with γ-secretase.Chem Med Chem,2019,14(10):1005-1010. [19] Auguet T, Bertran L, Binetti J, et al. Hepatocyte Notch signaling deregulation related to lipid metabolism in women with obesity and nonalcoholic fatty liver.Obesity (Silver Spring),2020,28(8):1487-1493. [20] Lee YH, Yun MR, Kim HM, et al. Exogenous administration of DLK1 ameliorates hepatic steatosis and regulates gluconeogenesis via activation of AMPK.Int J Obes (Lond),2016,40(2):356-365. |